222 related articles for article (PubMed ID: 21984468)
21. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.
Cirillo M; Venturini M; Ciccarelli L; Coati F; Bortolami O; Verlato G
Ann Oncol; 2009 Dec; 20(12):1929-35. PubMed ID: 19622510
[TBL] [Abstract][Full Text] [Related]
22. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
23. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
[TBL] [Abstract][Full Text] [Related]
24. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
Basch E; Rogak LJ; Dueck AC
Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
[TBL] [Abstract][Full Text] [Related]
25. Asking the right questions to get the right answers: using cognitive interviews to review the acceptability, comprehension and clinical meaningfulness of patient self-report adverse event items in oncology patients.
Holch P; Warrington L; Potrata B; Ziegler L; Hector C; Keding A; Harley C; Absolom K; Morris C; Bamforth L; Velikova G
Acta Oncol; 2016; 55(9-10):1220-1226. PubMed ID: 27551774
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
27. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Zhong X; Lim EA; Hershman DL; Moinpour CM; Unger J; Lee SM
J Oncol Pract; 2016 Mar; 12(3):e270-80, 245-6. PubMed ID: 26907453
[TBL] [Abstract][Full Text] [Related]
28. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
29. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
30. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
31. RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
Watkins-Bruner D; Scott C; Lawton C; DelRowe J; Rotman M; Buswell L; Beard C; Cella D
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):901-6. PubMed ID: 7591900
[TBL] [Abstract][Full Text] [Related]
32. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.
Galizia D; Milani A; Geuna E; Martinello R; Cagnazzo C; Foresto M; Longo V; Berchialla P; Solinas G; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Ballari AM; Aglietta M; Montemurro F
Cancer Med; 2018 Sep; 7(9):4339-4344. PubMed ID: 30030895
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
34. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
[TBL] [Abstract][Full Text] [Related]
35. Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.
Nyrop KA; Deal AM; Reeve BB; Basch E; Chen YT; Park JH; Shachar SS; Carey LA; Reeder-Hayes KE; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Lee JT; Wood WA; Muss HB
Cancer; 2020 Jul; 126(13):3084-3093. PubMed ID: 32315091
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
37. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
[TBL] [Abstract][Full Text] [Related]
39. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
40. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.
Kim J; Singh H; Ayalew K; Borror K; Campbell M; Johnson LL; Karesh A; Khin NA; Less JR; Menikoff J; Minasian L; Mitchell SA; Papadopoulos EJ; Piekarz RL; Prohaska KA; Thompson S; Sridhara R; Pazdur R; Kluetz PG
Clin Cancer Res; 2018 Apr; 24(8):1780-1784. PubMed ID: 29237718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
